Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease

March 7, 2017 updated by: Danna Jennings, Molecular NeuroImaging
The primary objective of this exploratory imaging study is to further characterize [18F]T807, an investigational PET radioligand for imaging Tau (thought to be a downstream biomarker indicative of neurodegeneration in conditions such as AD).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

16

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Connecticut
      • New Haven, Connecticut, United States, 06510
        • Molecular NeuroImaging, LLC

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

For all Subjects:

  • Written informed consent or assent is obtained
  • Female subjects/volunteers must be either surgically sterile (by means of hysterectomy, bilateral oophorectomy, or tubal ligation) or post-menopausal for at least 1 year or, if they are of childbearing potential, must commit to the use of two effective contraception methods for the duration of the study.
  • Male subjects/volunteers and their partners of childbearing potential must commit to the use of two effective methods of contraception, one of which should be a barrier method for male subjects.

Prodromal and Mild Alzheimer's Disease Subjects

  • Males and females aged between 50 and 90 years.
  • Study partner has noticed a recent gradual decrease in the subject's memory (e.g., over the prior 12 months), which the subject may or may not be aware of.
  • For prodromal subjects, abnormal memory function at screening or 4 weeks prior to screening based on the FCSRT-IR of:Free recall <17, or Total recall <40, or Free recall <20 and total recall <42.
  • Individuals with mild AD must meet the criteria based on the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association and Diagnostic and Statistical Manual of Mental Disorders, Version 5, criteria. This evidence may be compiled during screening but must be fully documented in the subject's study file before the baseline visit.
  • Have an MMSE (Folstein et al. 1975) score at screening >20.
  • Have an Amyvid (florbetapir F 18 injection) scan at screening that demonstrates amyloid binding based on qualitative analysis (visual read) that meets the criteria for AD.
  • Modified Hachinski Ischemia Scale (Moroney et al. 1997) score of ≤ 4.
  • A neuroimaging evaluation of the brain by MRI that supports a diagnosis of AD with no evidence of focal disease to account for dementia or MRI exclusion criteria.
  • Medications taken for symptomatic treatment of AD must be maintained on a stable dosage regimen for at least 4 weeks before the [18F]T807 imaging visit.
  • Able to participate in all scheduled evaluations.
  • The subject has an appropriate caregiver or community dwelling with a caregiver capable of accompanying the subject on all visits to the center as judged by the investigator.
  • In the opinion of the investigator, the subject and caregiver will be compliant and have a high probability of completing the study.

Healthy Volunteers

  • Males and females aged between 20 and 90 years. Younger healthy controls will be aged 20-49 and older healthy controls will be aged 50-90.
  • Healthy volunteers with no clinically relevant findings on physical examination at screening and upon reporting for the [18F]T807 imaging visit.
  • No suspicion of cognitive impairment/early dementia from MMSE as judged by the investigator (MMSE>28).
  • No concomitant medications, over-the-counter, supplement, or any other agent intended to improve cognition or prevent cognitive decline
  • A negative Amyvid (florbetapir F 18 injection) scan at screening based on qualitative analysis (visual read).

Exclusion Criteria:

For All subjects:

  • Current or prior history of any alcohol or drug abuse.
  • Severe systemic disease based on history and physical examination.
  • Positive result on urine screen for illicit drugs.
  • Laboratory tests with clinically significant abnormalities
  • Clinically significant unstable medical or psychiatric illness.
  • Positive test for hepatitis B or C or HIV.
  • Prior participation in other research protocols or clinical care in the last year such that radiation exposure is >15 mSv and participation in this study would require the subject/volunteer to exceed the annual limits.
  • Pregnancy or breastfeeding.
  • Current or prior history of coagulopathy.
  • The subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease.
  • History of significant drug and/or food allergies, anaphylactic/anaphylactoid reaction to any allergen.
  • Contraindication for arterial cannulation.
  • Unsuitable veins for repeated venipuncture.
  • MRI exclusion criteria include: non-AD pathology such as infectious disease, space-occupying lesions, normal pressure hydrocephalus, or any other abnormalities associated with significant CNS disease
  • Any lacunar infarct in a strategically important location known to lead to cognitive impairment such as the thalamus, hippocampus of either hemisphere, or head of the left caudate
  • Severe sub-cortical microvascular disease (Fazekas score of 3 for deep white matter hyperintensities) (Fazekas et al. 1987)
  • Territorial infarct or macroscopic hemorrhage (>10 mm)
  • Implants such as implanted cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS aneurysm clips or other medical implants that have not been certified for MRI, or history of claustrophobia in MRI
  • Observed claustrophobia at screening
  • Ferromagnetic foreign bodies, such as metal shrapnel or bullet fragments, need to be considered on an individual basis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: [18F]T807
At the [18F]T807 PET imaging visit, subjects will be given a bolus injection of no more than 10 mCi (370 MBq) of [18F]T807
Drug: [18F]T807
All enrolled subjects will undergo an [18F]T807 PET imaging visit. In addition, subjects with AD and aged volunteers will have one PET scan with Amyvid (florbetapir F 18 injection) as part of the screening activities to measure Aβ in the brain.
Other Names:
  • Amyvid
  • [18F]florbetapir

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quantitative evaluation of [18F]T807 as a potential PET radioligand for imaging Tau in patients with clinically characterized tauopathies
Time Frame: 1 year
To further characterize [18F]T807, an investigational PET radioligand for imaging Tau (thought to be a downstream biomarker indicative of neurodegeneration in conditions such as AD) and to assess the full quantitative evaluation of the PET outcome measures using [18F]T807 by pharmacokinetic (PK) modeling in order to derive a volume of distribution (VT) of [18F]T807 using arterial input function.
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Molecular NeuroImaging

Collaborators

Roche Pharma AG
Institute for Neurodegenerative Disorders

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2015

Primary Completion (Actual)

January 1, 2016

Study Completion (Actual)

January 1, 2016

Study Registration Dates

First Submitted

February 17, 2015

First Submitted That Met QC Criteria

February 23, 2015

First Posted (Estimate)

February 25, 2015

Study Record Updates

Last Update Posted (Actual)

March 8, 2017

Last Update Submitted That Met QC Criteria

March 7, 2017

Last Verified

March 1, 2017

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • [18F]T807

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Alzheimer's Disease (AD)

Clinical Trials on [18F]T807

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe